Lumora Named as ‘Company to Watch in 2015’ by Leading Industry Publisher

Cambridgeshire, UK, 24 March 2015 ... Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial markets, has been named as a company to watch in 2015 by Kalorama, a leading publisher of market research in medical markets.

The report, ‘The Market and Potential for Molecular Point of Care Diagnostics’, describes the current state of the market for molecular point of care diagnostics and its future potential, looking at new technologies and how these will impact the market. Named in the report are 75 companies to watch in 2015, which along with a number of the larger companies such as BioMerieux, Eiken, Life Technologies and Qiagen, also includes smaller companies such as Lumora who are bringing novel approaches to the rapidly developing market.

Lumora’s novel technologies, and in particular BART (Bioluminescent Assay in Real Time) are described in the report. The report focuses on its use in a clinical setting for hospital acquired infections and HIV monitoring.

Laurence Tisi, CEO of Lumora, said: “This report is yet another validation of our technology. Through our various technologies, such as BART, Lumora is able to provide cutting edge molecular point of care diagnostics where they are most needed, and in challenging areas such as low resource settings. We are very pleased to be named as one of the companies to watch in 2015, and to be in such company along with many of the established players in the molecular diagnostics space.”

Jim Reid, Chairman of Lumora commented “With the recent approval of the first CLIA (Clinical Laboratory Improvement Amendments) waived product in the USA this opens the market for huge expansion in point of care molecular diagnostics. Lumora has a number of proprietary technologies which will see it well placed to address this major opportunity and this report is confirmation of the company’s strong position in what will become a major multi-billion dollar market”.

For further information please contact:
Tony Stephenson, Director
Exitus Communications
Tel: +44 (0)7899 796655
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Notes to Editors:

About Lumora
Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora's easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is active in commercialising its technology and our development and commercialisation partners include international biotechnology, clinical diagnostic and industrial microbiology companies.

Lumora's corporate office is based just outside of Cambridge, England. The Company's investors include; Tate Lyle Ventures LP, Cambridge Enterprise (University of Cambridge), and Catapult Venture Managers Ltd.